Fujian South Pharmaceutical Co. Ltd.

September 30, 2015  –  Rochem International Inc. and Fujian South Pharmaceutical Co. Ltd., (FSP) are pleased to announce that FSP has passed their first U.S. FDA inspection in September, 2015. Rochem has worked closely with Fujian South Pharmaceutical Co. Ltd over the past five years, through extensive on-site training, audits, as well as providing sound technical support, to ensure that their operations are fully cGMP compliant. Fujian South Pharmaceutical Co. Ltd was established in 2001 and mainly produces Paclitaxel (natural and semi-synthetic), Docetaxel and 10-DAB III, based on its own vertical industrial chain from Taxus nursery, KSM extraction/purification and API manufacturing in dedicated facilities . Rochem is Fujian South Pharmaceutical Co. Ltd.’s U.S. and EU Site Agent as well as its Exclusive Distributor and Regulatory Agent for multiple drug master files (DMFs) and Certificates of Suitability (COSs).